Work

Personalized Medicine and Inhibition ofEGFRSignaling in Lung Cancer

Year: 2009
Type: editorial
Abstract: The concept underlying much of cancer therapy is that patients with specific types and stages of cancer should be treated according to standardized, predetermined protocols. However, recent advances in drug development, pharmacogenomics, and the molecular characterization of tumors — including genomewide RNA expression, DNA copy-number and sequence analyses, and microRNA and proteomic profiling — have the potential to allow individualized selection of treatment as determined by the characteristics of the patient and the tumor.In principle, targeted therapies attack cancer-cell–specific attributes that are essential for growth or survival (“oncogene addiction”) and avoid the potentially severe side effects of conventional cytotoxic . . .
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W1970015742
Cites: 10
Cited by: 194
Related to: 10